Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent...
PR Newswire·16d ago
More News
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC PR Newswire...
PR Newswire·22d ago
Lunai Bioworks, Inc. Issues Letter to Shareholders
Lunai Bioworks, Inc. Issues Letter to Shareholders Lunai Bioworks, Inc. Issues Letter to Shareholders PR Newswire SACRAMENTO, Calif., Feb. 9, 2026 SACRAMENTO, Calif., Feb. 9, 2026 /PRNewswire...
PR Newswire·26d ago
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data Lunai Bioworks (NASDAQ: LNAI...
PR Newswire·26d ago
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard...
PR Newswire·1mo ago
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use...
PR Newswire·1mo ago
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market Lunai Bioworks Identifies Three...
The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.
Stocktwits·3mo ago
Top Biotech Stocks To Follow Now - November 5th
Danaher, Vertex Pharmaceuticals, Recursion Pharmaceuticals, Moderna, and Lunai Bioworks are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are...